Investment House LLC cut its position in C R Bard Inc (NYSE:BCR) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,387 shares of the medical instruments supplier’s stock after selling 743 shares during the period. Investment House LLC’s holdings in C R Bard were worth $2,778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Havens Advisors LLC increased its stake in shares of C R Bard by 105.3% in the third quarter. Havens Advisors LLC now owns 25,000 shares of the medical instruments supplier’s stock worth $8,013,000 after purchasing an additional 12,823 shares in the last quarter. Atlantic Trust Group LLC boosted its position in shares of C R Bard by 19.6% during the third quarter. Atlantic Trust Group LLC now owns 14,382 shares of the medical instruments supplier’s stock worth $4,609,000 after acquiring an additional 2,359 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of C R Bard by 16.3% during the third quarter. JPMorgan Chase & Co. now owns 542,368 shares of the medical instruments supplier’s stock worth $173,222,000 after acquiring an additional 76,185 shares during the last quarter. Alpine Global Management LLC bought a new position in shares of C R Bard during the second quarter worth $12,165,000. Finally, Banco BTG Pactual S.A. bought a new position in shares of C R Bard during the second quarter worth $7,271,000. 79.11% of the stock is owned by hedge funds and other institutional investors.

In other C R Bard news, insider Christopher S. Holland sold 38,242 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $334.04, for a total transaction of $12,774,357.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jim C. Beasley sold 15,044 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $332.00, for a total transaction of $4,994,608.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 111,258 shares of company stock valued at $37,099,342. 0.80% of the stock is owned by company insiders.

Shares of C R Bard Inc (NYSE BCR) traded down $1.95 during trading hours on Wednesday, hitting $331.24. 4,714,800 shares of the company were exchanged, compared to its average volume of 679,456. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. C R Bard Inc has a 12-month low of $222.42 and a 12-month high of $337.73. The company has a market capitalization of $24,140.00, a price-to-earnings ratio of 43.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52.

A number of brokerages recently weighed in on BCR. ValuEngine lowered shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Cowen restated a “hold” rating and set a $317.00 target price on shares of C R Bard in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research report on Tuesday, December 26th. Needham & Company LLC restated a “hold” rating on shares of C R Bard in a research report on Thursday, October 26th. Finally, Barclays upped their target price on shares of C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. C R Bard currently has an average rating of “Hold” and a consensus price target of $320.83.

WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/01/31/investment-house-llc-has-2-78-million-stake-in-c-r-bard-inc-bcr.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.